Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Medtech Guidance Tracker: June 2021

Executive Summary

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-six documents have been posted on the tracker since its last update.

You may also be interested in...



FDA: Companies Servicing Products Could Get In Hot Water For Remanufacturing

A new draft guidance from the US FDA clarifies what it considers to be remanufacturing. Companies remanufacturing devices are regulated by the agency and may require new premarket applications.

How The EU’s Device Nomenclature Operates: Free Of Charge And Accessible To All

The EU’s device nomenclature is a vital key to operating the Eudamed database. A new EU document explains how it operates, who can use it and where to access the device naming scheme.

ICH Makes Progress On Tackling Safety Data ‘Overload’

Changes to an ICH guideline could help drug companies that are being deluged with post-approval safety information to cut down on noisy, low-value data.

Topics

UsernamePublicRestriction

Register

MT144153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel